Search - tctmd.com

Displaying 521 - 540 of 643

$Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction Primary results of the PARAGON-HF trial$

Presentation ESC 2019

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Presenter: Scott D. Solomon

September 01, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

Todd Neale

September 01, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

RELAX-AHF-2: Lack of Benefit With Serelaxin in Acute HF Still a Puzzle for Investigators

L.A. McKeown

August 21, 2019

News Daily News

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

Todd Neale

August 20, 2019

News Industry News

preCARDIA Enrolls First Patient in Early Feasibility Study

August 15, 2019

News Industry News

Miracor Medical Starts PiCSO-AMI-I Randomized Study in EU

July 25, 2019

News Industry News

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

June 26, 2019

News Conference News ESC Heart Failure 2019

Steep Rise in PCI for Ischemic Heart Failure Seen in Sweden, but Survival Favors CABG

Shelley Wood

May 28, 2019

News Conference News ESC Heart Failure 2019

Weaning Off Diuretics in Stable Heart Failure? ReBIC-1 Hints at Possibilities

Shelley Wood

May 28, 2019

News Conference News ESC Heart Failure 2019

Rivaroxaban Cuts Major Stroke Risk in COMMANDER HF Post Hoc Analysis

Shelley Wood

May 26, 2019

News Daily News

Proportionate and Disproportionate MR: A ‘Framework’ for MitraClip and Medical Therapy

Shelley Wood

May 09, 2019

News Daily News

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Michael O'Riordan

May 06, 2019

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

News Daily News

Mortality From Heart Failure Increasing in United States

Michael O'Riordan

May 06, 2019

News Daily News

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

Michael O'Riordan

April 10, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

News Conference News ACC 2019

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

Michael O'Riordan

March 25, 2019

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Shelley Wood

March 11, 2019

Advertisement

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

RELAX-AHF-2: Lack of Benefit With Serelaxin in Acute HF Still a Puzzle for Investigators

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

preCARDIA Enrolls First Patient in Early Feasibility Study

Miracor Medical Starts PiCSO-AMI-I Randomized Study in EU

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Steep Rise in PCI for Ischemic Heart Failure Seen in Sweden, but Survival Favors CABG

Weaning Off Diuretics in Stable Heart Failure? ReBIC-1 Hints at Possibilities

Rivaroxaban Cuts Major Stroke Risk in COMMANDER HF Post Hoc Analysis

Proportionate and Disproportionate MR: A ‘Framework’ for MitraClip and Medical Therapy

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Mortality From Heart Failure Increasing in United States

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content